Meiji Seika Pharma's Nacubactam Shows Promising Results in Phase III Trial for Carbapenem-Resistant Infections — Meiji Seika Pharma Co., Ltd.

Event summary

Meiji Seika Pharma's global Phase III trial (Integral-2) for nacubactam, a novel β-lactamase inhibitor, met primary endpoints with success rates of 44.4% for cefepime/nacubactam and 50.0% for aztreonam/nacubactam, compared to 26.1% for Best Available Therapy (BAT).
The trial enrolled patients with infections caused by carbapenem-resistant Gram-negative bacteria, excluding Acinetobacter species.
No major clinical safety concerns were observed in the study.
Meiji Seika Pharma submitted a New Drug Application (NDA) in Japan for nacubactam in December 2025 based on results from two Phase III studies.

The big picture

Meiji Seika Pharma's positive Phase III results for nacubactam come at a critical time as global health authorities grapple with the rising threat of antimicrobial resistance. The dual mechanism of nacubactam, targeting both β-lactamase enzymes and penicillin-binding protein 2 (PBP2), sets it apart from existing inhibitors and could offer a new line of defense against carbapenem-resistant Enterobacterales (CRE). The successful trial results and subsequent NDA submission mark a significant step in the company's efforts to combat this growing public health challenge.

What we're watching

Regulatory Approval: Whether the NDA submission will lead to regulatory approval in Japan and other markets, given the promising Phase III results.
Market Adoption: The pace at which nacubactam could be adopted in clinical settings for treating carbapenem-resistant infections, pending approval.
Competitive Landscape: How Meiji Seika Pharma positions nacubactam against existing and emerging treatments for antimicrobial resistance.